ADMA Biologics (ADMA) said Monday it has received approval from the US Food and Drug Administration for its yield enhancement production process.
The process is expected to raise production by roughly 20% from the same starting plasma volume, the biopharmaceutical company added.
ADMA's stock rose 12% in recent Monday premarket activity.